UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 166

Sortiert nach

Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial

Diabetologia, 2018-10, Vol.61 (10), p.2155-2163

2018

Link zum Volltext

Verfügbarkeit prüfen

The kisspeptin-GnRH pathway in human reproductive health and disease

Human reproduction update, 2014-07, Vol.20 (4), p.485-500

2014

Link zum Volltext

Verfügbarkeit prüfen

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial

Diabetes care, 2018-02, Vol.41 (2), p.356-363

2018

Link zum Volltext

Verfügbarkeit prüfen

Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial

Circulation (New York, N.Y.), 2019-03, Vol.139 (11), p.1384-1395

2019

Link zum Volltext

Verfügbarkeit prüfen

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial

European heart journal, 2018-02, Vol.39 (5), p.363-370

2018

Link zum Volltext

Verfügbarkeit prüfen

Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control

Circulation (New York, N.Y.), 2018-10, Vol.138 (17), p.1904-1907

2018

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial

Age and ageing, 2019-11, Vol.48 (6), p.859-866

2019

Link zum Volltext

Verfügbarkeit prüfen

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial

Diabetologia, 2018-08, Vol.61 (8), p.1712-1723

2018

Link zum Volltext

Verfügbarkeit prüfen

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials

Diabetes care, 2018-12, Vol.41 (12), p.2560-2569

2018

Link zum Volltext

Verfügbarkeit prüfen

Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose‐lowering therapy?

Diabetes, obesity & metabolism, 2020-04, Vol.22 (4), p.631-639

2020

Link zum Volltext

Verfügbarkeit prüfen

Neurokinin B Regulates Gonadotropin Secretion, Ovarian Follicle Growth, and the Timing of Ovulation in Healthy Women

The journal of clinical endocrinology and metabolism, 2018-01, Vol.103 (1), p.95-104

2018

Link zum Volltext

Verfügbarkeit prüfen

Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational Trial

Clinical journal of the American Society of Nephrology, 2020-10, Vol.15 (10), p.1433-1444

2020

Link zum Volltext

Verfügbarkeit prüfen

FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later

Diabetes, obesity & metabolism, 2019-05, Vol.21 (5), p.1073-1078

2019

Link zum Volltext

Verfügbarkeit prüfen

Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME

Diabetologia, 2018-07, Vol.61 (7), p.1522-1527

2018

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA‐REG OUTCOME trial

European journal of heart failure, 2020-01, Vol.22 (1), p.126-135

2020

Link zum Volltext

Verfügbarkeit prüfen

Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial

European heart journal, 2020-01, Vol.41 (2), p.209-217

2020

Link zum Volltext

Verfügbarkeit prüfen

Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial

Diabetes care, 2019-10, Vol.42 (10), p.1930-1938

2019

Link zum Volltext

Verfügbarkeit prüfen

Kisspeptin and neurokinin B interactions in modulating gonadotropin secretion in women with polycystic ovary syndrome

Human reproduction (Oxford), 2020-06, Vol.35 (6), p.1421-1431

2020

Link zum Volltext

Verfügbarkeit prüfen

Interactions Between Neurokinin B and Kisspeptin in Mediating Estrogen Feedback in Healthy Women

The journal of clinical endocrinology and metabolism, 2016-12, Vol.101 (12), p.4628-4636

2016

Link zum Volltext

Verfügbarkeit prüfen

Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality: Insights From the EMPA-REG OUTCOME Trial

Circulation (New York, N.Y.), 2019-03, Vol.139 (11), p.1458-1460

2019

Link zum Volltext

Verfügbarkeit prüfen

Kisspeptin and the Hypothalamic Control of Reproduction: Lessons from the Human

Endocrinology (Philadelphia), 2012-11, Vol.153 (11), p.5130-5136

2012

Link zum Volltext

Verfügbarkeit prüfen

Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA‐REG OUTCOME trial

Diabetes, obesity & metabolism, 2020-12, Vol.22 (12), p.2335-2347

2020

Link zum Volltext

Verfügbarkeit prüfen

Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial

Diabetes care, 2019-04, Vol.42 (4), p.e53-e55

2019

Link zum Volltext

Verfügbarkeit prüfen

Neurokinin 3 Receptor Antagonism Reveals Roles for Neurokinin B in the Regulation of Gonadotropin Secretion and Hot Flashes in Postmenopausal Women

Neuroendocrinology, 2018-02, Vol.106 (2), p.148-157

2018

Link zum Volltext

Verfügbarkeit prüfen

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

Clinical kidney journal, 2018-12, Vol.11 (6), p.749-761

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 166

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(142)
Mit Volltextzugriff
(165)

Publikationsform

Sprache

Englisch
(166)
Japanisch
(16)

Erscheinungsjahr

n.n

Thema

Science & Technology
(86)
Life Sciences & Biomedicine
(84)
Diabetes
(57)
Humans
(54)
Diabetes Mellitus
(50)
Endocrinology & Metabolism
(46)
Male
(32)
Cardiovascular System & Cardiology
(30)
Female
(30)
Diabetes Mellitus, Type 2 - Drug Therapy
(29)
Heart Failure
(29)
Cardiac & Cardiovascular Systems
(28)
Empagliflozin
(26)
Mortality
(26)
Type 2 Diabetes
(25)
Cardiovascular Disease
(24)
Cardiovascular Diseases
(23)
Middle Aged
(20)
Treatment Outcome
(20)
Aged
(18)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial

The kisspeptin-GnRH pathway in human reproductive health and disease

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial

Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial

Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control

Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials

Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose‐lowering therapy?

Neurokinin B Regulates Gonadotropin Secretion, Ovarian Follicle Growth, and the Timing of Ovulation in Healthy Women

Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational Trial

FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later

Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME

Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA‐REG OUTCOME trial

Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial

Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial

Kisspeptin and neurokinin B interactions in modulating gonadotropin secretion in women with polycystic ovary syndrome

Interactions Between Neurokinin B and Kisspeptin in Mediating Estrogen Feedback in Healthy Women

Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality: Insights From the EMPA-REG OUTCOME Trial

Kisspeptin and the Hypothalamic Control of Reproduction: Lessons from the Human

Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA‐REG OUTCOME trial

Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial

Neurokinin 3 Receptor Antagonism Reveals Roles for Neurokinin B in the Regulation of Gonadotropin Secretion and Hot Flashes in Postmenopausal Women

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

Suchergebnisse filtern